Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.
Sign Up to like & getrecommendations! Published in 2020 at "Advances in experimental medicine and biology"
DOI: 10.1007/978-3-030-43032-0_1
Abstract: Osteosarcoma was initially resistant to chemotherapy that worked for Ewing sarcoma and rhabdomyosarcoma as well as other chemotherapeutic agents available in the 1960s. In the early 1970s, responses of osteosarcoma to adriamycin were reported, and… read more here.
Keywords: chemotherapy; historical perspective; adjuvant neoadjuvant; chemotherapy osteosarcoma ... See more keywords
Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of adolescent and young adult oncology"
DOI: 10.1089/jayao.2019.0085
Abstract: Purpose: The French standard chemotherapy for osteosarcoma combines high-dose methotrexate (HDM) and etoposide-ifosfamide (EI) in children and adolescents, and API-AI (doxorubicin-cisplatin-ifosfamide) in adults. We herein present the results of M-EI and API-AI in 18- to… read more here.
Keywords: chemotherapy; etoposide ifosfamide; chemotherapy osteosarcoma; doxorubicin cisplatin ... See more keywords